T
SPRY icon

Tidemark’s ARS Pharmaceuticals SPRY Stock Holding History

Tidemark’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35K Hold
169
– – ﹤0.01% 720
2026
Q1 		$1.36K Hold
169
– – ﹤0.01% 681
2025
Q4 		$1.97K Hold
169
– – ﹤0.01% 577
2025
Q3 		$1.7K Sell
169
-1,500
-90% -$21.5K ﹤0.01% 609
2025
Q2 		$29.1K Buy
1,669
+169
+11% +$2.44K 0.01% 313
2025
Q1 		$18.9K Hold
1,500
– – 0.01% 349
2024
Q4 		$15.8K Buy
+1,500
New +$21K 0.01% 383

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Tidemark's SPRY Position: Q2 2026 in Review

Tidemark held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 169 shares worth $1.35K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

Tidemark first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $29.1K in Q2 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Tidemark held 169 shares of ARS Pharmaceuticals worth $1.35K as of Q2 2026.
  • Tidemark left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #720 holding.
  • Tidemark first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Tidemark's ARS Pharmaceuticals position peaked at $29.1K in Q2 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.